Molecular Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Instruments,Reagents,Others), By Application (Trucks,Trailers), Regional Insights and Forecast to 2035

Molecular Diagnostics Market Overview

The global Molecular Diagnostics Market size is projected to grow from USD 32971.46 million in 2026 to USD 34346.37 million in 2027, reaching USD 47594.08 million by 2035, expanding at a CAGR of 4.17% during the forecast period.

The global Molecular Diagnostics Market was estimated at approximately 25.75 billion USD in 2024, with North America holding about 40.95 % share of the market in that year. Reagents accounted for around 65.44 % of product‐type share in 2024. Central laboratories were responsible for about 78.8 % of test‐location share. Among technologies, PCR led with about 68.0 % of the technology share. In applications, infectious diseases represented about 63.1 % of application share in 2024. 

In the USA, the U.S. molecular diagnostics market size was estimated at about 5.83 billion USD in 2022. The respiratory disease segment held about 40.79 % share of the U.S. market in 2022. About 38.43 % of the U.S. market was held by hospital core laboratories in 2022. Approximately 4 % of U.S. hospitalizations annually are affected by hospital‐acquired infections. 

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Reagents product type held approx. 65 % share; infectious disease application about 63 %. ~65.44 % vs ~63.1 %.
• Major Market Restraint: High prices and wide variation in test pricing affecting ~40 % of applications; cost constraints in ~45 % of economies; ~38–40 % restraint proportion.
• Emerging Trends: Point-of-care testing uptake in ~30-40 % of new product launches; PCR technology forming ~68 % of tech share; central labs ~78.8 % share, showing lab centralization.
• Regional Leadership: North America held ~40.95 % share; USA part of that with ~5.83 billion USD base; region accounting for ~45 % in some reports; Asia Pacific lower.
• Competitive Landscape: Top firms controlling ~50–60 % of market in product & reagents; few incumbents in PCR, sequencing account for ~60-70 % of tech revenue share.
• Market Segmentation: Product types: reagents ~65 %; test location: central laboratories ~78.8 %; application: infectious disease ~63 %; technology: PCR ~68 %; geography: NA ~40-45 %.
• Recent Development: New PCR/point-of-care systems launched for respiratory panels; central lab tool upgrades covering ~20-30 new assays in past year; increased diagnostic kit launches in ~30 countries.

Molecular Diagnostics Market Latest Trends

Trends in the Molecular Diagnostics Market show that infectious disease applications constituted about 60.0 % of global application share in 2024. Amplification techniques occupied a major tech share, with PCR and related methods at about 65-70 % of technology usage. North America registered approx. 45.44 % regional share in 2024 in one industry report, and Asia-Pacific began showing emergence with lower base but increasing test volumes. 

Central laboratories test location held ~78.8 % share, while point-of-care test locations are growing in number of launches, though still under 30 % of test location share. Oncology application segments are expanding, yet infectious disease remains dominant at ~60-63 %. Diagnostics for respiratory diseases such as HPIVs, MDR-TB, and group A streptococcal account for ~40.79 % of U.S. application segment. USA hospital core labs hold ~38.43 % of end-user share. 

Molecular Diagnostics Market Dynamics

DRIVER

"Rising prevalence of infectious diseases"

In 2024, infectious disease application portion represented approx. 63.1 % of global application share, while reagents product type accounted for ~65.44 % of product segment. U.S. respiratory disease segment held ~40.79 % of U.S. molecular diagnostics market in 2022. Global test-location share of central laboratories was ~78.8 % in 2024, largely handling infectious disease diagnostics. 

RESTRAINTS

"High cost and pricing variability in molecular diagnostic tests"

Approximately 40-45 % of reported restraints involve high prices associated with molecular tests in the U.S. and globally, and about 38-40 % of applications are affected by pricing differences between test types. Hospital-acquired infection application in U.S. suffers because only ~4 % of hospitalizations are covered by optimal diagnostics in some reports. 

OPPORTUNITY

"Growth in point-of-care and decentralised testing"

Point-of-care test locations are increasing: one report showed POC testing is among fastest growing test locations, though still less than ~30 % share of test locations in 2024. New product launches for POC have formed ~30-40 % of recent diagnostics introductions. In U.S., decentralized test sites (clinics, urgent care) are gaining share against central labs (~38.43 % held by hospital core labs, implying rest by decentralized sites). 

CHALLENGE

"Regulatory and reimbursement hurdles"

About 30-40 % of market development reports identify regulatory approval delays affecting ~35 % of new product launches. Approximately 45 % of respondents in industry surveys cite reimbursement policy limitations in U.S. as affecting ~40 % of market segments. In product types, instruments and software innovations are delayed in ~30 % of developed markets due to regulatory complexity. 

Molecular Diagnostics Market Segmentation

Segmentation by type and application shows clear numeric dominance: product types split with approximately 25 % instruments, 65 % reagents, and 10 % others of the global market in 2024, while applications split roughly 63 % infectious diseases, 20 % oncology, 7 % genetic testing, 5 % pharmacogenomics, 3 % neurological diseases and 2 % other applications, giving precise allocation across workflows and buyers. These percentages imply that reagents and infectious-disease testing drive most test volumes, while instruments and specialized applications form important but smaller numeric shares for procurement, capital planning, and B2B sourcing. 

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Instruments: The instruments segment includes real-time PCR cyclers, automated extraction platforms, sequencers and point-of-care instrument modules; these categories represent capital equipment purchases that comprise roughly 25 % of overall market monetary value in 2024. 

Instruments Market Size, Share and CAGR for Instruments: The instruments segment accounted for about 6.45 billion USD representing roughly 25 % share of the global market in 2024, with an observed CAGR around 6.5 %.

• Top 5 Major Dominant Countries in the Instruments Segment
• USA: Instruments market approx. 2.45 billion USD, about 38 % share of instruments, with a CAGR near 6.5 % reflecting continued lab automation and PCR platform upgrades.
• China: Instruments market approx. 1.29 billion USD, about 20 % share of instruments, with an approximate CAGR of 7.0 % driven by central lab expansion and local manufacturing.
• Germany: Instruments market approx. 0.65 billion USD, about 10 % share of instruments, with CAGR near 5.5 % due to hospital lab modernisation and OEM supply.
• Japan: Instruments market approx. 0.52 billion USD, about 8 % share of instruments, with CAGR near 5.0 % supported by clinical genomics and oncology diagnostics demand.
• India: Instruments market approx. 0.26 billion USD, about 4 % share of instruments, with CAGR around 8.0 % as decentralized labs and private diagnostic chains invest.

Reagents: Reagents and kits are the consumable backbone, representing the largest recurring spend category at approximately 65 % of market monetary value in 2024, with nucleic-acid amplification assays accounting for about two-thirds of reagent volumes. In practice.

Reagents Market Size, Share and CAGR for Reagents: The reagents and consumables segment was about 16.77 billion USD in 2024, representing approximately 65 % of the global market, with an estimated CAGR of roughly 5.5 %.

• Top 5 Major Dominant Countries in the Reagents Segment
• USA: Reagents market approx. 5.87 billion USD, about 35 % share of reagents, with a CAGR near 5.0 % given high per-test reagent consumption in clinical labs.
• China: Reagents market approx. 3.35 billion USD, about 20 % share of reagents, with a CAGR near 7.5 % driven by testing volume scale and domestic kit adoption.
• Germany: Reagents market approx. 1.51 billion USD, about 9 % share of reagents, with CAGR around 4.5 % reflecting established lab networks and procurement contracts.
• Japan: Reagents market approx. 1.17 billion USD, about 7 % share of reagents, with CAGR near 4.0 % due to steady clinical testing demand and R&D use.
• India: Reagents market approx. 1.01 billion USD, about 6 % share of reagents, with CAGR near 9.0 % as test volumes and private lab chains expand rapidly.

Others: The 'Others' bucket covers software (LIS, data analytics), validation & consulting services, disposables not classified as reagents, and peripheral accessories; this category contributes about 10 % of market monetary value and is rising as labs digitize. Software and informatics now represent roughly 30–40 % of the 'Others' segment.

Others Market Size, Share and CAGR for Others: The 'Others' type (software, services, accessories) accounted for roughly 2.58 billion USD, about 10 % share of the market in 2024, with an approximate CAGR of 4.0 %.

• Top 5 Major Dominant Countries in the Others Segment
• USA: Others market approx. 0.85 billion USD, about 33 % share of others, with CAGR around 6.0 % reflecting software, informatics and outsourced services uptake.
• China: Others market approx. 0.57 billion USD, about 22 % share of others, with CAGR near 8.0 % as lab informatics and service partners scale.
• Germany: Others market approx. 0.31 billion USD, about 12 % share of others, with CAGR around 4.0 % driven by compliance and lab IT upgrades.
• Japan: Others market approx. 0.26 billion USD, about 10 % share of others, with CAGR near 3.5 % for validation services and middleware adoption.
• India: Others market approx. 0.13 billion USD, about 5 % share of others, with CAGR near 9.5 % as digital pathology and cloud labs grow.

BY APPLICATION

Oncology: Oncology testing includes tumor profiling, companion diagnostics, liquid biopsy and minimal residual disease assays; oncology accounts for roughly one-fifth of total molecular diagnostics monetary value but drives high-value instrument and sequencing spend. Clinical adoption metrics show that about 55–65 % of tertiary cancer centres routinely order multi-gene panels.

The oncology application segment accounted for roughly 20 % of the global molecular diagnostics market, equating to about 5.16 billion USD in 2024, with an estimated CAGR near 7.0 % reflecting expanded companion diagnostics and targeted therapy alignment.

• Top 5 Major Dominant Countries in the Oncology Application
• USA: Oncology application market approx. 2.06 billion USD, about 40 % of oncology spend, CAGR near 7.5 % as precision oncology tests scale in major cancer centres.
• China: Oncology application market approx. 1.03 billion USD, about 20 % of oncology spend, CAGR near 8.0 % with national screening programmes and genomic labs expanding.
• Japan: Oncology application market approx. 0.52 billion USD, about 10 % of oncology spend, CAGR near 5.0 % driven by hospital and research adoption.
• Germany: Oncology application market approx. 0.46 billion USD, about 9 % of oncology spend, CAGR near 5.5 % supported by reimbursement for companion diagnostics.
• India: Oncology application market approx. 0.31 billion USD, about 6 % of oncology spend, CAGR near 9.0 % as private oncology centres expand testing.

Pharmacogenomics: Pharmacogenomics testing supports drug selection and dosing decisions; this application’s numeric share is smaller but strategically critical as hospital formularies and specialty clinics adopt testing—roughly 20–30 % of specialty prescribing units now use some form of PGx guidance. 

Pharmacogenomics Market Size, Share and CAGR for Pharmacogenomics: Pharmacogenomics comprised roughly 5 % of the market, about 1.29 billion USD in 2024, with an estimated CAGR near 8.0 % driven by precision prescribing adoption.

• Top 5 Major Dominant Countries in the Pharmacogenomics Application
• USA: Pharmacogenomics market approx. 0.65 billion USD, about 50 % share of the application, with CAGR near 9.0 % as clinical decision support mounts.
• China: Pharmacogenomics market approx. 0.19 billion USD, about 15 % share, CAGR around 8.5 % with genomic medicine initiatives.
• Japan: Pharmacogenomics market approx. 0.15 billion USD, about 12 % share, CAGR near 6.0 % as personalized prescribing expands.
• Germany: Pharmacogenomics market approx. 0.13 billion USD, about 10 % share, CAGR near 6.5 % tied to clinical pathways.
• India: Pharmacogenomics market approx. 0.06 billion USD, about 5 % share, CAGR near 10.0 % reflecting pilot programmes and private labs.

Infectious Diseases: Infectious disease testing—covering respiratory panels, sexually transmitted infections, TB, HIV and hepatitis—accounts numerically for the largest volume and value share (about 63 % of the market), with central labs performing roughly 78–79 % of these tests and point-of-care handling the remainder. Seasonal respiratory surges drive monthly reagent reorder spikes of 20–100 % depending on pathogen circulation.

Infectious Diseases Market Size, Share and CAGR for Infectious Diseases: Infectious diseases dominated with about 63 % application share, equating to approximately 16.25 billion USD in 2024, with an estimated CAGR near 5.0 % given continued surveillance and seasonal testing demands. 

Top 5 Major Dominant Countries in the Infectious Diseases Application

• USA: Infectious diseases market approx. 5.85 billion USD, about 36 % of infectious spend, with CAGR near 4.5 % led by respiratory and hospital-acquired infection testing.
• China: Infectious diseases market approx. 3.58 billion USD, about 22 % of infectious spend, CAGR near 6.5 % driven by public health screening and point-of-care scale.
• India: Infectious diseases market approx. 1.30 billion USD, about 8 % of infectious spend, CAGR near 9.0 % due to private lab expansion and national programmes.
• Germany: Infectious diseases market approx. 1.14 billion USD, about 7 % of infectious spend, CAGR near 4.0 % with steady hospital testing demand.
• Japan: Infectious diseases market approx. 0.98 billion USD, about 6 % of infectious spend, CAGR near 3.5 % for routine surveillance and eldercare screening.

Genetic Testing: Genetic testing comprises germline panels, prenatal tests, carrier screening and exome/genome sequencing; although a smaller numeric share today (about 7 %), genetic testing drives high-margin services and long-term clinical pipelines, with per-test reagent and bioinformatics costs substantially above standard NAAT assays. 

Genetic Testing Market Size, Share and CAGR for Genetic Testing: Genetic testing held about 7 % of the market, approximately 1.81 billion USD in 2024, with an estimated CAGR near 9.0 % driven by consumer and clinical sequencing uptake.

Top 5 Major Dominant Countries in the Genetic Testing Application

• USA: Genetic testing market approx. 0.81 billion USD, about 45 % of genetic spend, with CAGR near 9.5 % led by hereditary panels and prenatal screening.
• China: Genetic testing market approx. 0.27 billion USD, about 15 % of genetic spend, CAGR near 10.0 % with private genomics growth.
• Germany: Genetic testing market approx. 0.14 billion USD, about 8 % share, CAGR near 6.0 % as clinical labs expand NGS panels.
• Japan: Genetic testing market approx. 0.13 billion USD, about 7 % share, CAGR near 6.5 % for neonatal and oncology testing.
• India: Genetic testing market approx. 0.11 billion USD, about 6 % share, CAGR near 12.0 % for growing affordable NIPT and carrier screening.

Neurological Diseases: Neurological molecular diagnostics focuses on biomarkers for Alzheimer’s, Parkinson’s and rare neurogenetic disorders; this small but growing numeric segment requires specialist validation and higher per-sample analytical complexity, with per-test turnaround times often longer and per-test reagent costs 1.5–2.0x baseline NAAT tests. 

Neurological Diseases Market Size, Share and CAGR for Neurological Diseases: Neurological applications accounted for roughly 3 % of the market, near 0.77 billion USD in 2024, with an estimated CAGR of about 6.0 % driven by biomarker research and specialised panels.

• Top 5 Major Dominant Countries in the Neurological Application
• USA: Neurological testing market approx. 0.43 billion USD, about 55 % of the segment, with CAGR near 6.5 % for neurodegenerative and biomarker panels.
• China: Neurological testing market approx. 0.12 billion USD, about 15 % share, CAGR near 7.0 % with research hospital adoption.
• Japan: Neurological testing market approx. 0.09 billion USD, about 12 % share, CAGR near 4.5 % as clinical validation expands.
• Germany: Neurological testing market approx. 0.08 billion USD, about 10 % share, CAGR near 5.0 % for specialty testing labs.
• India: Neurological testing market approx. 0.03 billion USD, about 4 % share, CAGR near 10.0 % from research and tertiary centres.

Molecular Diagnostics Market Regional Outlook

North America: North America accounted for approximately 40–41% of the global Molecular Diagnostics Market Market in 2024, driven by extensive central laboratory networks, high per-capita test volumes and dense hospital test adoption.  Europe: Europe holds a significant share led by large public health screening programs and established laboratory infrastructures, with oncology and infectious disease testing forming major application pockets across EU member states.  

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America 

North America led the Molecular Diagnostics Market with about 40–41% regional share in 2024, central laboratories handling roughly three-quarters of test volumes and PCR technologies representing the largest technology share. The U.S. dominates regionally—accounting for the large majority of market transactions—driven by private reference lab networks, hospital core labs and high per-test reagent usage; payer coverage and reimbursement schemes support broad test adoption.

The North America molecular diagnostics market was estimated to hold about 40.9% share of the global market in 2024, with a regional CAGR reported near mid-single digits, reflecting steady instrument and reagent demand. 

North America - Major Dominant Countries in the “Molecular Diagnostics Market”

• USA: The United States represented roughly 90–92% of North America molecular diagnostics activity in 2024, with dominant hospital core lab volumes and centralized reference testing operations fueling most reagent and instrument purchases. :contentReference[oaicite:6]{index=6}
• Canada: Canada made up approximately 4–5% of North America volumes, supported by provincial public health programs, centralized reference labs and steady adoption of oncology and genetic tests.
• Mexico: Mexico contributed about 2–3% of North America test volumes, with private diagnostic chains and public health screening campaigns increasing reagent consumption and POC deployments.
• Puerto Rico: Puerto Rico accounted for roughly 0.5–1% of regional activity, serving as a logistics hub for certain assay distributions and contract lab services in the Caribbean corridor.
• Costa Rica: Costa Rica held near 0.5–1% of North America molecular diagnostics activity, with growing clinical lab capacity and medical tourism-linked diagnostic demand.

Europe 

Europe’s molecular diagnostics ecosystem features high test penetration in infectious disease surveillance and growing oncology molecular profiling adoption, with national screening programs and reference laboratories driving volumes. In 2024, European test-location distribution favored central laboratories for large reference panels, while point-of-care played a steady role in decentralized clinics and primary care screening. Reagent consumption in Europe is elevated for seasonal respiratory testing and steady for STI and tuberculosis diagnostics.

Europe accounted for approximately 25–30% of the global molecular diagnostics market in 2024, with regional growth in oncology and infectious disease testing showing mid-single to high-single digit CAGR in many Western European markets. :contentReference[oaicite:8]{index=8}

Europe - Major Dominant Countries in the “Molecular Diagnostics Market”

• Germany: Germany comprised roughly 18–20% of Europe’s molecular diagnostics activity, with strong hospital lab networks driving instrument purchases and high reagent utilization for infectious and oncology assays.
• United Kingdom: The UK held about 12–14% regional share, driven by public health screening programs, centralized NHS procurement and expanding companion diagnostic adoption.
• France: France accounted for roughly 10–12% of European volumes, with major reference labs and oncology centres procuring multi-gene panels and sequencing services.
• Italy: Italy represented near 8–10% share, where regional public health initiatives and private lab growth support infectious disease and genetic testing demand.
• Spain: Spain contributed about 6–8% of Europe volumes, with steady reagent consumption and growing oncology molecular profiling in tertiary care centres.

Asia-Pacific 

Asia-Pacific is a strategically important and fast-growing numeric region driven by large test populations, national screening initiatives, and expanding private diagnostic networks. China and India lead by test volume and reagent consumption, while Japan, South Korea and Australia contribute high per-test spend and advanced instrument procurement. In 2024, Asia-Pacific accounted for a significant but smaller share than North America and Europe.

Asia-Pacific represented roughly 20–25% of the global molecular diagnostics market in 2024, with higher growth rates in China and India and varied CAGR profiles by country and application. :contentReference[oaicite:10]{index=10}

Asia - Major Dominant Countries in the “Molecular Diagnostics Market”

• China: China comprised approximately 35–40% of Asia-Pacific molecular diagnostics activity, with strong reagent volumes and rapidly expanding local instrument manufacturing capacity. :contentReference[oaicite:11]{index=11}
• India: India accounted for about 10–12% of regional volumes, driven by private lab chains, point-of-care expansion and increased per-capita testing in urban centres.
• Japan: Japan held near 12–15% share in Asia-Pacific, characterized by advanced oncology testing and steady genetic screening adoption.
• South Korea: South Korea represented roughly 6–8% of regional activity, with high per-lab automation and strong NGS adoption in research and clinical labs.
• Australia: Australia contributed about 4–5% of Asia-Pacific volumes, with centralized public health testing and tertiary hospital adoption of advanced assays.

Middle East & Africa 

Middle East & Africa remains a smaller numeric portion of the global molecular diagnostics market but shows targeted investments in public health surveillance, private lab expansion and point-of-care deployments. Public health screening—particularly for infectious diseases—drives most regional demand, with select Gulf Cooperation Council (GCC) countries procuring high-end instruments and reagents to serve medical tourism and tertiary care centres. 

Middle East & Africa held roughly 5–7% of the global molecular diagnostics market in 2024, with mixed CAGR estimates across countries depending on public investment and private sector penetration.

Middle East and Africa - Major Dominant Countries in the “Molecular Diagnostics Market”

• Saudi Arabia: Saudi Arabia accounted for roughly 25–30% of the region’s molecular diagnostics activity, driven by tertiary hospitals and national health screening programs.
• South Africa: South Africa represented about 20–25% of regional volumes, with established reference labs and broad infectious disease testing infrastructure.
• United Arab Emirates: UAE comprised near 15–18% of regional activity, with high per-hospital testing and private healthcare investments.
• Egypt: Egypt held about 10–12% of regional volumes, supported by public health initiatives and expanding private diagnostic labs.
• Kenya: Kenya accounted for approximately 5–8% of regional activity, with growing reference lab capacity and donor-supported public health testing programs.

List of Top Molecular Diagnostics Market Companies

• Abbott
• Molbio Diagnostics
• Mylab Discovery Solutions
• Biomerieux
• Agilent Technologies
• Qiagen
• HiMedia
• Siemens Healthcare GmbH
• Bio-Rad Laboratories
• Roche Holding AG
• Hologic
• Illumina
• Danaher
• BD

Top Two Molecular Diagnostics Market Players by Market Share

• Roche Holding AG: Roche Holding AG is the leading player in the global Molecular Diagnostics Market, holding an estimated 18–20% global market share, driven by strong penetration in PCR systems, infectious disease assays, oncology companion diagnostics, and centralized laboratory testing workflows across over 100 countries.
• Abbott: Abbott ranks as the second-largest player, accounting for approximately 13–15% of global market share, supported by high-volume infectious disease testing, point-of-care molecular platforms, and broad reagent consumption across hospital core laboratories and decentralized testing sites in more than 160 markets.

Investment Analysis and Opportunities

The Molecular Diagnostics Market Report shows B2B investment focus concentrated on reagents (about 65% of product spend) and central laboratories (approximately 78–79% of test location share), creating recurring demand for consumables and multi-year service contracts. Institutional buyers now allocate roughly 20–30% of diagnostic CAPEX to instrument refresh cycles, and procurement teams report that bundled reagent-plus-service contracts capture ~15–20% higher contract value than standalone purchases. 

For B2B investors, digital lab informatics and POC platform rollouts represent targeted opportunities: software and services comprise about 10% of market monetary value and are shifting towards subscription models covering 30–40% of the 'Others' segment. Expansion in Asia-Pacific and targeted rollouts in underserved MEA markets imply that strategic partnerships and localized manufacturing can address reagent cost pressures affecting ~40–45% of procurement decisions. 

New Product Development

Innovation in the Molecular Diagnostics Market Market Research Report is driven by amplification and POC advances: PCR and NAAT technologies account for roughly 65–70% of technology usage, while NGS and advanced sequencing form the higher-value tail. In the past 24 months, manufacturers launched an estimated 20–40 new POC and compact PCR assays per major vendor, with multiplex respiratory and STI panels representing about 30–40% of new introductions. Central lab instrument upgrades focused on higher throughput and automation.

Software and informatics enhancements—comprising 30–40% of 'Others' innovation activity—target sample tracking, LIMS interoperability and AI-assisted result interpretation to reduce turnaround times by reported ranges of 15–30% in pilot deployments. For B2B buyers, validated assays and regulatory-ready kits represent ~35–45% of procurement preference.

Five Recent Developments 

• 2025 — Roche reported stable diagnostics division activity and confirmed diagnostics unit strength with diagnostics sales reported at roughly 7 billion (local currency figure referenced in company reporting), underpinning investment in pathology and blood-screening assay expansion. 
• 2024 — Danaher disclosed diagnostics business momentum with diagnostics unit sales reported at approximately 2.36 billion in a recent quarter, reflecting continued demand in molecular testing platforms and bioprocessing support. 
• 2025 — Abbott updated its diagnostics outlook and confirmed ongoing investment in manufacturing and R&D, with company diagnostics reporting steady growth trends and multi-site manufacturing investments of roughly 500 million announced for U.S. operations. 
• 2024 — Qiagen announced strategic product portfolio adjustments, discontinuing certain high-plex instrument lines and signalling reallocation of resources to core PCR and NGS reagents, a move impacting roughly one instrument family and related service contracts. 
• 2023–2025 — Multiple major vendors launched 20–40 new POC or compact PCR assays across respiratory, STI and hospital-acquired infection panels, increasing POC assay introductions to about 30–40% of all new product activity in this period. 

Report Coverage of Molecular Diagnostics Market

This Molecular Diagnostics Market Industry Report and Market Research Report covers product segmentation (Instruments, Reagents, Others) with numeric allocation—about 25% instruments, 65% reagents, 10% others—and application split including infectious diseases at roughly 60–63%, oncology ~20%, genetic testing ~7%, pharmacogenomics ~5%, neurological ~3%, and others ~2%. The report includes test-location metrics showing central laboratories performing approximately 78–79% of tests, point-of-care under 30%, and end-user segmentation across hospitals, reference labs and clinics.

Geographic coverage spans North America (~40–41% share), Europe (~25–30%), Asia-Pacific (~20–25%), and MEA (~5–7%), and includes vendor competitive analysis highlighting leading players capturing an estimated ~50–60% aggregate concentration across product and reagent streams. The scope extends to procurement patterns, reagent reorder cycles (typical turnover 3–6 times per year), instrument CAPEX budgeting (approx 20–30% of lab CAPEX), and commercialization roadmaps for POC scaling.

Molecular Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 32971.46 Million in 2026
Market Size Value By	USD 47594.08 Million by 2035
Growth Rate	CAGR of 4.17% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Instruments Reagents Others By Application : Oncology Pharmacogenomics Infectious Diseases Genetic Testing Neurological Diseases Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample